In 2020, Congress for the first time included “peripheral neuropathy” as an eligible condition for study through a $370 million fund administered by the Department of Defense (DoD) known as the “Peer Reviewed Medical Research Program (PRMRP).” This important breakthrough was a direct result of the nationwide advocacy of the peripheral neuropathy community, led by FPN.
This accomplishment has allowed our research community to apply for funding from a federal program to which they previously did not have access.
Every year, Congress determines the conditions that are eligible for study through the PRMRP by listing them in the Senate version of the annual Defense Appropriations Act.
Gregory Maassen is so close to the end of his e-bike tour across the U.S. Won’t you help in achieving his goals of completing his cross-country tour in San Francisco on August 2, and raising $150,000 for FPN?
Share your voice today to help support more productive conversations regarding diabetes and associated nerve pain. Create a memory aid (mnemonic) that encourages people suffering from diabetic nerve pain of the feet to discuss symptoms, important healthcare reminders and potential treatment solutions with their physicians!
FDA Approves Vutrisiran to Treat hATTR Amyloidosis
The approval was based off results from the phase 3 HELIOS-A study, which showed that vutrisiran met its primary end point of change in modified Neuropathy Impairment Score + 7 over a nine-month treatment period.
